Anti-IL12+IL23 (Briakinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-IL12+IL23 (Briakinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (ADC-W-2029)
This ADC product is comprised of an anti-IL12+IL23 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
Name
IL12+IL23
Alternative Names
IL12+IL23
Overview
Interleukin-12 (IL-12; one of the most important T helper 1 (Th1) cytokines) is a component of the complex signal network between lymphoid and neoplastic cells. Systemic or local administration of IL-12 upregulates vascular endothelial adhesion molecule-1 on the endothelial surface, recruits leukocytes to the tumor site, and leads to ischemic–hemorrhagic necrosis of the tumor. IL-12 also inhibits tumor angiogenesis. Interleukin-23 (IL-23) is a heterodimeric cytokine composed of an IL12B (IL-12p40) subunit (that is shared with IL12) and the IL23A (IL-23p19) subunit. A functional receptor for IL-23 (the IL-23 receptor) has been identified and is composed of IL-12R β1 and IL-23R.
ADC Antibody
Overview
Human Anti-IL12+IL23 IgG1-lambda antibody, Briakinumab
Generic name
Briakinumab
Host animal
Human
ADC Linker
Name
MC-Vc-PAB-DMEA-(PEG2)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
duocarmycin SA
Description
Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.